Hints and tips:
...“By holding Grail separate while proceedings are ongoing, Illumina is positioned to abide by whatever final decision is reached in these legal processes,” the statement said....
...In 2016 Dr Fischer was handed the mission of holding a “citizens debate” on vaccine policy following measles outbreaks and declining vaccination rates....
...But Mr Garg credits Singapore, where its holding company is based, for making it easy for him to access capital....
...This dual role of holding consumer and health data is already the subject of a lawsuit against Google and the University of Chicago....
...Its main assets are Novo Nordisk, the healthcare company specialising in diabetes and hormones, and Novozymes, an industrial biotechnology company....
...Now GlaxoSmithKline, the largest UK drug manufacturer by sales, is teaming up with Alphabet, Google’s holding company, to develop an entirely different approach for the 21st century: bioelectronics....
...The deep discounting announced by Sanofi on Tuesday provides further evidence that insurance companies and PBMs are having some success at holding down drug prices in the US after years of budget-busting...
...The move comes amid growing pressure from regulators and consumers for a reduction in sugar and salt, which are linked to obesity and diabetes....
...Belle International Holdings, the country’s second-largest footwear company by sales, said its 2016 shoe sales slid 9 per cent year on year, while trainers revenue jumped 16 per cent....
...A powerful new force in bioelectronics – using electrical signals rather than chemical or biological drugs to treat disease – has been created by GlaxoSmithKline in partnership with Alphabet, Google’s holding...
...GlaxoSmithKline has teamed up with Alphabet, Google’s holding company, to treat disease through miniature implants that affect electrical signalling along nerves, with the aim of creating a powerful new...
...Sanofi and AbbVie have both targeted oncology as an area for expansion as they seek to reduce dependence on their best-selling products — Lantus for diabetes and Humira for inflammatory diseases, respectively...
...In an interview with the Financial Times, Mr Brandicourt admitted that a downturn in diabetes drugs — responsible for a fifth of total revenues — had made his job more difficult as Sanofi's best-selling...
...They got fat, developed diabetes, became zombified by low culture: what they did was considered unequivocally bad....
...Google has hired a senior health researcher to lead a push into the mental health sector, as its ambitions beyond internet search expand to fit the new blueprint laid out with its reinvention as holding...
...Life science innovation is one of the pillars of the Alphabet holding company set up by Google this year as an umbrella for the group’s increasingly diverse activities....
...Mr Baum agrees that the most competitive fields such as respiratory and diabetes drugs will face pressure....
...More clinical-grade apps are gradually emerging, such as glucose monitors to help manage diabetes....
...Yet there are growing signs of similar behaviour in other areas, including treatments for asthma and diabetes, as the groups that fund US healthcare take a tougher approach to containing costs....
...Although his portfolio runs the gamut from banks and insurers to railroad, manufacturing and energy companies, it includes substantial holdings in candy, ice cream, chewing gum, soft drinks and the heavily...
...MannKind, the developer of a new inhaled insulin therapy, soared after Sanofi, the French pharmaceutical group, forged a pact to license and develop the diabetes treatment....
...Such companies figure in Sectoral’s top 10 holdings (see table). Lupin, for instance, is an Indian generic drug maker that is looking to expand further beyond its domestic market....
...The new Takeda management faces a challenge to revive growth after the loss of patent protection on its best-selling Actos diabetes drug in the US and rising competition in Japan, which accounts for 45 per...
...Investors who know the stakes will be holding their breath....
...He has shown greater decision in cutting costs and buying out a diabetes joint venture with Bristol-Myers-Squibb for $4.3bn....
International Edition